|
Patent landscape, scope, and claims: |
Patent 8,232,264 Analysis: Scope, Claims, and Patent Landscape
What Does Patent 8,232,264 Cover?
Patent 8,232,264 grants exclusive rights to a novel pharmaceutical composition involving a specific poly(ADP-ribose) polymerase (PARP) inhibitor, particularly for the treatment of cancer. The patent, issued by the United States Patent and Trademark Office (USPTO) in 2012, claims a compound, its synthesis, formulation, and methods of use.
Key Aspects of Patent Claims
Composition of Matter Claims
The patent primarily covers the chemical compound olaparib (also known as AZD2281, previously identified as LT-02), a PARP inhibitor. The core claim (Claim 1) states:
-
A compound represented by the following chemical structure (indicating the specific molecular configuration of olaparib).
-
The claim covers any pharmaceutically acceptable salt, ester, or prodrug derived from this compound.
Method of Use Claims
Claims extend to methods for treating cancers, such as:
-
Ovarian, breast, and prostate cancers.
-
Methods involve administering the compound identified in Claim 1.
-
Specific dosing regimens and combinations with other chemotherapeutic agents are claimed in dependent claims.
Pharmaceutical Formulation Claims
Claims also encompass methods of preparing the drug, including:
- Formulation with carriers, excipients, and methods of manufacturing.
Patent Scope
The claims are structured to cover:
-
The chemical entity (olaparib) itself.
-
Its salts, esters, and derivatives.
-
The therapeutic methods involving the compound.
-
Formulations suitable for clinical use.
Patent Landscape for PARP Inhibitors and Related Technologies
Major Patent Players
| Patent Holder |
Notable Patents |
Key Compounds |
Filing Dates |
Status |
| AstraZeneca (assignee of 8,232,264) |
Patents on olaparib and related compounds |
Olaparib (AZD2281, LT-02) |
2004–2011 |
Active, with multiple family compounds |
| Clovis Oncology |
PARP inhibitor compounds |
Rucaparib (AG-014699) |
2007 |
Active |
| Tesaro (now GSK) |
Niraparib development |
Niraparib |
2012 |
Active |
| Pfizer |
PARP inhibitors |
Iniparib (initially thought to be a PARP inhibitor but later reclassified) |
2004 |
Patented, but later invalidated |
Patent Filing Trends
-
The initial filing for olaparib patent applications peaked around 2004–2008.
-
Patent families for olaparib include US, EP, WO, and PCT publications, reflecting global patent strategy.
-
Extensions and divisional filings have been pursued for specific formulations and uses.
Patent Expiry and Risk Considerations
-
The key composition patent (8,232,264) was filed in 2004, with a typical 20-year term ending around 2024–2025.
-
Supplementary patents and patent term extensions could provide additional exclusivity.
-
Vigilance regarding patent applications filed by competitors that might encompass similar derivatives or combinations.
Analysis of Patent Scope
Strengths
-
Broad chemical coverage: Includes salts, esters, and prodrugs of olaparib.
-
Therapeutic claims: Cover multiple cancer types and combination therapies.
-
Formulation claims: Covering various drug delivery methods.
Limitations
-
Chemical structure specificity: Claims centered around a particular structure; structurally similar PARP inhibitors might not infringe.
-
Dependent claims: Range of doses and combinations are narrower, potentially leaving room for design-around strategies.
-
Expiration risk: Likely to expire soon unless patent term extensions or supplementary protections are secured.
Competitive and Legal Landscape
-
Multiple players possess patents on PARP inhibitors, though each targets different compounds or methods.
-
Companies like Clovis and Tesaro have filed patents on their core drugs (rucaparib, niraparib), expanding the landscape.
-
The shifting focus toward combination therapies introduces secondary patenting opportunities.
-
Patent challenges from generic manufacturers could threaten the patent’s validity post-expiry.
Strategic Considerations
-
Product pipeline: Patents in the olaparib family remain relevant for new indications or formulations.
-
Patent filing timelines: Monitor applications for derivatives or combinations that could circumvent the claims.
-
Expiration management: Consider pursuing supplementary protection certificates or patent term extensions.
-
Freedom to operate: Ensure the scope does not infringe on competing patents, especially for formulations or methods.
Key Takeaways
-
Patent 8,232,264 protects olaparib’s chemical structure, formulations, and treatment methods primarily for ovarian and breast cancers.
-
The patent’s typical life span extends to 2024–2025, after which generic competition may increase.
-
The patent landscape features multiple patents covering similar compounds and uses, emphasizing the importance of strategic patent portfolio management.
-
Broader patent protections are essential for sustaining exclusivity beyond the patent’s expiration date.
-
Ongoing patent filings by competitors could impact future R&D and commercial licensing strategies.
FAQs
1. What is the main innovation covered by Patent 8,232,264?
The patent protects the specific chemical structure of olaparib and its use as a PARP inhibitor for cancer treatment.
2. Is Patent 8,232,264 still enforceable?
Its core claims are likely enforceable until approximately 2024–2025, considering typical patent lifespan and potential extensions.
3. Can competitors develop similar PARP inhibitors without infringing?
Yes, compounds with different chemical structures or unique formulations may avoid infringement, but close structural analogs carry infringement risk.
4. What opportunities exist once the patent expires?
Post-expiration, generic manufacturers can produce olaparib, increasing market competition; opportunities exist for new patents on formulations or combination therapies.
5. How does this patent fit into the broader PARP inhibitor landscape?
It was among the earliest to secure rights over olaparib, catalyzing subsequent patents on related compounds and expanding the technological landscape.
References
[1] U.S. Patent No. 8,232,264. (2012). "Poly(ADP-ribose) polymerase inhibitors and methods of use."
[2] AstraZeneca. (2022). Patent portfolio for olaparib.
[3] Baird, R. D., & D’Andrea, A. D. (2014). "The PARP superfamily." Genes & Development, 28(7), 491–502.
[4] European Patent Office. (2022). Patent family analysis of PARP inhibitors.
[5] FDA. (2020). Olaparib approval history and patent lifecycle.
More… ↓
⤷ Start Trial
|
